Journal of Ethnopharmacology · 2018 · 76 citations · 40 references
MedicineOncologyPharmacologyCancer PharmacologyCarcinogenesisMolecular OncologyColorectal CancerMetastatic Disease TreatmentAnticancer ActivityAnticancer Compound ScreeningCancer Cell ApoptosisColorectal Carcinogenesis PathophysiologyFlow Cytometric Cell AnalysisHif-1 SignalingTraditional Chinese MedicineTumor Metastasis Biology
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese medicine has been utilized for the treatment of cancer. Jianpi Jiedu decoction (JPJD), a traditional Chinese medicine formula, has been used for the treatment of colorectal cancer for decades. However, the underlying molecular mechanistic basis for the effect of JPJD on colorectal cancer is poorly understood. AIM OF THE STUDY: The aim of this study was to identify the effects of JPJD on human colon cancer cells in vitro as well as in vivo and to investigate the mechanistic basis for the anticancer effect of JPJD. MATERIALS AND METHODS: The in vitro antitumor activity of JPJD was assessed by MTT assay, flow cytometric analysis, wound-healing assay, transwell assays, and tube formation assays in order to assess cell activity, apoptosis, migration, invasion, and angiogenesis, respectively. The anticancer properties of JPJD in vivo were assessed by immunohistochemistry in a nude mouse xenograft model of HCT116 cells. In addition, the level of mTOR/HIF-1α/VEGF signaling pathway proteins in HCT116 cells and tumor tissue was evaluated by immunoblotting. RESULTS: In vitro, JPJD significantly inhibited colorectal cancer cell lines viability and proliferation. Flow cytometry analysis demonstrated JPJD to induce HCT116 cell apoptosis. Additionally, JPJD effectively suppressed tumor cell migration, invasion, and angiogenesis by inhibiting the mTOR/HIF-1α/VEGF signaling pathway. In vivo, JPJD significantly inhibited HCT116 tumor growth in athymic nude mice, decreased the levels of CD34 as well as VEGF, and downregulated the mTOR/HIF-1α/VEGF pathway. CONCLUSIONS: JPJD treatment produced anti-colorectal tumor effects by inhibiting tumorigenesis, metastasis, as well as angiogenesis through the mTOR/HIF-1α/VEGF pathway. Thus, these results provide a strong rationale for the therapeutic use of JPJD in cancer treatment. Further studies are required to investigate the mechanisms underlying anti-CRC effect of JPJD.
40
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +11
Katayoon Pakravan, Sadegh Babashah, Majid Sadeghizadeh et al. · Cellular Oncology · 2017 · 346 citations · Full text
Medicine, Cell Biology, Oncology +17
Dan Cao, Mei Hou, Yong‐Song Guan et al. · BMC Cancer · 2009 · 245 citations · Full text
Peramaiyan Rajendran, Feng Li, Muthu K. Shanmugam et al. · Cancer Prevention Research · 2012 · 158 citations
Medicine, Oncology, Pharmacology +15